CALL FOR POSTER ABSTRACTS
Submission of abstracts for presentation as a poster during the 31st CINP World Congress is greatly encouraged until the closing deadline of Friday 12th January 2018.
All submitted abstracts will be reviewed by the Local Organising Committee (LOC) “real time” and up to the closing date which is Friday 12th January 2018. Notification of acceptance/rejection of the poster will be communicated through email by late February 2018. The LOC will evaluate each abstract using the following criteria; relevance to CINP, standard of English, objectivity of statement, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression. All accepted abstracts will be published online in the International Journal of Neuropsychopharmacology (IJNP) and on the congress website www.cinp.org/vienna for all registered delegates to view.
– Abstracts must be submitted in English.
– The successful participant is committed to presenting their poster at the time allocated to them by the ISPC.
– The CINP Central Office must be informed of any changes in author(s) by end of February 2018 to ensure the final programme is correct.
– If the original presenting author is for any reason unable to fulfil this commitment at the Congress, then a co-author should take over this responsibility.
– All poster submitters must complete a registration form through the online system, available here and provide payment of fees by Friday 12th January 2018. Posters submitted without a paid registration fee may not be published in the Abstract Book
– Posters must be submitted under the correct topic, see list of topics here
– If a poster is not accepted, then the submitted will have the right to receive a full payment of registration fee if subsequently unable to attend the Congress.
– CINP encourages the use of Neuroscience-based Nomenclature (NbN-2) terminology for psychotropic medications, as it reflects contemporary pharmacological knowledge, rather than arbitrary descriptors based on indications or chemical structure.
– The title of the abstract must clearly indicate the content of the poster with abbreviations being avoided.
– Abbreviations may only be used in the text of the abstract if clearly defined before use.
– Abstracts must be a maximum of 300 words excluding title, references, author name and affiliation.
– Please ensure that the abstract does not contain any spelling, grammatical or scientific errors as these will not be checked before production in the final programme.
All submitters must ensure that the abstract clearly states the following:
– Specific objective of the study
– Methods used (if applicable)
– Summary of results
– Conclusions reached
Poster sessions will be held on each of the three days of the congress from 11:30 – 13:00 on Level 1. Presenting authors must be in attendance during their allocated session to provide further information and feedback to any congress delegate who may ask any questions. Posters will be grouped by topic with each author being informed of their session day and time in advance of the meeting.
An award will be presented each day for the best clinical, translational and basic neuroscience posters. These awards are to encourage and highlight young scientists (under 35 years old) who are actively involved in clinical and pre-clinical research. Submitters can indicate whether they wish to be considered for an award during their online submission.